Massachusetts General Hospital wouldn't seem like a natural fit for a center devoted to mind-altering drugs. But this week, MGH launched the Center for the Neuroscience of Psychedelics to study the potential of psilocybin and other psychoactive drugs to treat conditions such as depression, addiction, trauma, and more. The new center at MGH signifies that the field of psychedelic therapy has arrived. Inspiration came from the search for ways to ease the misery of patients whose mental illness is resistant to traditional treatments. Psychedelics are known to facilitate "plasticity" in the brain, increasing its capacity for change, and [director Jerrold] Rosenbaum said his team wanted to understand how these agents "move the brain to change in a way that can address many of the most anguishing forms of human suffering." The MGH center combines the disciplines of psychiatry, brain imaging, genomic medicine, and chemical biology. Some of the initial work involving patients will use psilocybin and be directed at rumination " the stuck, repetitive thought patterns that underlie several conditions, from addiction to obsessive-compulsive disorder. The future of the center's research is boundless, since psychedelics' role in neuroplasticity and neuritogenesis " the ability to build new synapses " may be useful in palliative care with terminally ill patients as well as in combatting neurodegenerative diseases such as Parkinson's and Alzheimer's.